GlassScriptPhysician profile
Michael J Germain
NPI 1376533117
$442,821.43
in general payments reported to CMS, 2019-2025
34 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $61K · 2021: $76K · 2022: $96K · 2023: $96K · 2024: $36K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Honoraria: $49K · Consulting Fee: $21K · Travel and Lodging: $11K · Food and Beverage: $4,635 · Education: $91.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,440.25 |
| Honoraria | $48,945.00 |
| Consulting Fee | $21,250.00 |
| Travel and Lodging | $10,511.90 |
| Food and Beverage | $4,635.45 |
| Education | $91.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $74,762.65 | 2019-2023 | Veltassa |
| Glaxosmithkline, LLC. | $56,620.74 | 2020-2025 | Jesduvroq, Benlysta |
| Alexion Pharmaceuticals, INC. | $53,029.89 | 2019-2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $50,625.47 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $41,614.33 | 2019-2023 | Lokelma, Farxiga, Flumist Quadrivalent |
| Horizon Therapeutics Plc | $27,664.78 | 2019-2023 | Krystexxa |
| Veloxis Pharmaceuticals, INC. | $25,817.42 | 2019-2024 | Envarsus |
| Rockwell Medical, INC. | $24,341.97 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $23,940.73 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $16,913.73 | 2021 | |
| Travere Therapeutics, INC. | $13,443.70 | 2019-2024 | |
| Amgen INC. | $10,674.77 | 2021-2024 | Tavneos, Krystexxa |
| Ani Pharmaceuticals, INC. | $9,713.92 | 2021-2023 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $7,274.12 | 2020 | |
| Akebia Therapeutics INC | $2,412.69 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,256.95 | 2021-2024 | |
| Opko Pharmaceuticals, LLC | $722.58 | 2019-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $537.26 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $410.27 | 2020-2022 | |
| Medtronic, INC. | $325.00 | 2021 | |
| Mallinckrodt Hospital Products INC. | $235.64 | 2022-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $156.54 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.43 | 2021-2023 | Gattex |
| Daiichi Sankyo INC. | $52.44 | 2019 | |
| Eurofins Viracor, LLC | $33.65 | 2022 | |
| Genzyme Corporation | $30.79 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $28.20 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $23.13 | 2023 | Inpefa |
| Strongbridge US INC. | $19.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.46 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Germain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.